Economist – Page 5 – Go Job Zone

Time is money in drug development – Healthcare Economist

June 3, 2024

0 Comments

Time is money in drug development – Healthcare Economist

Delays in drug approvals cost pharmaceutical firms money. These costs include both lost sales as well as additional cost if clinical trials need to ...

Recent Medicare attempts to lower drug prices (beyond IRA) – Healthcare Economist

May 29, 2024

0 Comments

Recent Medicare attempts to lower drug prices (beyond IRA) – Healthcare Economist

Recently, the Inflation Reduction Act (IRA) is getting a lot of attention, particularly for its provision that allows CMS to start drug price negotiation ...

Helping the paralyzed move – Healthcare Economist

May 21, 2024

0 Comments

Helping the paralyzed move – Healthcare Economist

Technology is amazing. From The Economist: Fourteen years ago, Melanie Reid, a journalist, fell off a horse and broke ...

May 21, 2024

0 Comments

A primer on brand-name prescription drug contracting – Healthcare Economist

The above is the title of a helpful primer from Kenney and Keast (2024). I summarize some key points below. Provide an overview of ...

May 13, 2024

0 Comments

Part 3 – Healthcare Economist

See my previous posts on IRA price negotiation on drug selection (Part 1) and manufacturer data submission (Part 2). Today we will talk about ...

May 9, 2024

0 Comments

Part 1 – Healthcare Economist

CMS released guidance on IRA price negotiation last week. Below are some highlights regarding how drugs will be selected. Which drugs are eligible for ...

Risk Adjustment and Incentives for Upcoding in Medicare – Healthcare Economist

May 6, 2024

0 Comments

Risk Adjustment and Incentives for Upcoding in Medicare – Healthcare Economist

To account for differences in disease burden across a Medicare Advantage (MA) plans patient population, uses risk adjustment based on patient disease burden. Specifically, ...

FDA’s Biosimilars Action Plan – Healthcare Economist

May 1, 2024

0 Comments

FDA’s Biosimilars Action Plan – Healthcare Economist

In July 2018, FDA released the Biosimilars Action Plan (BAP), which outlined FDA’s approach for expanding access to biosimilars ...

Do patients value improvements in progression-free survival? – Healthcare Economist

April 23, 2024

0 Comments

Do patients value improvements in progression-free survival? – Healthcare Economist

Progression-free survival (PFS) is a surrogate endpoint is defined as follows (by ChatGPT): In essence, PFS refers to the length of time during a ...

What would happen if we eliminated medical debt? – Healthcare Economist

April 19, 2024

0 Comments

What would happen if we eliminated medical debt? – Healthcare Economist

Medical debt in the U.S. is a major problem. While over 90% of individuals have health insurance, many people ...

Tag: Economist

Time is money in drug development – Healthcare Economist

Recent Medicare attempts to lower drug prices (beyond IRA) – Healthcare Economist

Helping the paralyzed move – Healthcare Economist

A primer on brand-name prescription drug contracting – Healthcare Economist

Part 3 – Healthcare Economist

Part 1 – Healthcare Economist

Risk Adjustment and Incentives for Upcoding in Medicare – Healthcare Economist

FDA’s Biosimilars Action Plan – Healthcare Economist

Do patients value improvements in progression-free survival? – Healthcare Economist

What would happen if we eliminated medical debt? – Healthcare Economist

Call us

(469) 663-8558

For Candidates

Helpful Resources

About Us

Posts tagged "Economist"

Call us

(469) 663-8558

For Candidates

Helpful Resources

About Us

Ready to find your dream job?​

Ready to find your dream job?​

Ready to find your dream job?

Ready to find your dream job?